businesspress24.com - Atossa Genetics to Announce Second Quarter 2013 Results on Wednesday, August 14, 2013
 

Atossa Genetics to Announce Second Quarter 2013 Results on Wednesday, August 14, 2013

ID: 1252205

(firmenpresse) - SEATTLE, WA -- (Marketwired) -- 08/06/13 -- (NASDAQ: ATOS), The Breast Health Company™, today announced that it will issue financial results and corporate highlights for the quarter ended June 30, 2013, following the close of market on Wednesday, August 14, 2013.

Management will host a conference call on Wednesday, August 14, 2013, at 4:45 pm Eastern time to review financial results and corporate highlights, including a slide presentation by Dr. Steven C. Quay, Chairman, Chief Executive Officer and President. Participating on the call in addition to Dr. Quay will be Kyle Guse, CFO and General Counsel, and Chris Destro, Vice President of Sales and Marketing. Following management's formal remarks, there will be a question and answer session.

To listen to the call by phone, interested parties within the U.S. may dial 866-652-5200 or 412-317-6060 for international callers. All callers should ask for the Atossa Genetics conference call. For your convenience, you may pre-register for the call by clicking here: .

The conference call and slides will also be available through a live webcast at .

A replay of the call will be available one hour after the end of the call through September 16, 2013, and can be accessed via Atossa's website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international). The replay conference ID number is 10031764.



Atossa Genetics, Inc. is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, the National Reference Laboratory for Breast Health, Inc. (NRLBH), patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information on Atossa, please visit . For additional information on the ForeCYTE test and the National Reference Laboratory for Breast Health, please visit .









Atossa Genetics, Inc.
Kyle Guse
CFO and General Counsel
(O) 800-351-3902


MBS Value Partners
Matthew D. Haines (Investors)
Managing Director
(O) 212-710-9686


JQA Partners
Jules Abraham (Media)
Principal
(O) 917-885-7378


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Titan Medical Inc. Announces Results for the Three and Six Months Ended June 30, 2013
Attorneys at Fitzgerald & Fitzgerald Settle New York Birth Injury Lawsuit for $3,500,000.00
Bereitgestellt von Benutzer: Marketwired
Datum: 06.08.2013 - 14:01 Uhr
Sprache: Deutsch
News-ID 1252205
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

SEATTLE, WA


Phone:

Kategorie:

Healthcare


Anmerkungen:


Diese Pressemitteilung wurde bisher 121 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Atossa Genetics to Announce Second Quarter 2013 Results on Wednesday, August 14, 2013
"
steht unter der journalistisch-redaktionellen Verantwortung von

Atossa Genetics, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Atossa Genetics, Inc.



 

Who is online

All members: 10 578
Register today: 0
Register yesterday: 4
Members online: 0
Guests online: 69


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.